Highlights •Ablation of IRF4 induces transplant acceptance by establishing T cell dysfunction •IRF4 represses PD-1, Helios, and other molecules associated with T cell dysfunction •Irf4‒/‒ T cell dysfunction is initially reversible but later becomes irreversible •Trametinib inhibits IRF4, abrogates EAE development, and prolongs allograft survival
Wenhao Chen, Ph.D., a scientist in the Immunobiology and Transplant Science Center at the Houston Methodist Research Institute, and his colleagues have identified a critical switch that controls T-cell function and dysfunction and have discovered a pathway to target it...
Read More
Recent Comments